Vimarsana
Biggest News Aggregation in the World

Generic Defendant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Generic Defendant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Generic Defendant Today - Breaking & Trending Today

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchase - Vimarsana News

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchase

CHICAGO--(BUSINESS WIRE)--If You Purchased, Paid for, or Provided Reimbursement for the Alzheimer’s Disease Drug Namenda XR or Namenda IR and its AB-rated generic equivalents, between April 14, 2010 through December 31, 2017 (the estimated date that the anticompetitive effects of Generic Defendants’ unlawful conduct...

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation - Vimarsana News

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

CHICAGO, Dec. 5, 2022 /PRNewswire/ -- If You Purchased, Paid for, or Provided Reimbursement for the Alzheimer's Disease Drug Namenda XR or Namenda...

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchase - Vimarsana News

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchase

CHICAGO--(BUSINESS WIRE)--If You Purchased, Paid for, or Provided Reimbursement for the Alzheimer’s Disease Drug Namenda XR or Namenda IR and its AB-rated generic equivalents, between April 14, 2010 through December 31, 2017 (the estimated date that the anticompetitive effects of Generic Defendants’ unlawful conduct...

Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of - Vimarsana News

Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of

On August 13, 2021, in a decision that largely flew under antitrust and patent practitioners' radars, U.S. District Judge Lucy H. Koh mostly denied a motion to dismiss in the alleged "reverse payment" case...

Source: mondaq.com
Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of "Profit Crushing Competition" | Haug Partners LLP - Vimarsana News

Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of "Profit Crushing Competition" | Haug Partners LLP

On August 13, 2021, in a decision that largely flew under antitrust and patent practitioners’ radars, U.S. District Judge Lucy H. Koh mostly denied a motion to dismiss in the alleged...